strong trikafta launch drive revenu ep
total non-gaap cf sale billion exclud million orkambi
adjust beat estim street consensu billion bring total cf
sale billion strong trikafta sale million first quarter launch
drove beat notabl trikafta appear cannib symdeko/symkevi global
sale slow million non-gaap dilut ep beat street
estim forecast cf sale billion in-lin billion
guidanc billion look non-gaap dilut ep growth
beyond cf remain optimist
updat partner crispr pipelin progress reiter overweight
rate increas price target lower opex
healthi trikafta launch drive cf sale forecast non-
cf sale billion driven rapid adopt trikafta
sold million includ million inventori build trikafta prescript
includ new patient start importantli among het/min patient
previous access cftr therapi homozyg patient switch
orkambi and/or symdeko end trikafta appear cannib
symdeko/symkevi global sale slow million orkambi
million quarter expect trikafta european launch year new
reimburs agreement uk franc could provid expand access
vertex therapi europ vertex provid cf sale guidanc billion
forecast billion year maintain billion estim
increas price vertex provid non-gaap opex guidanc
billion bring opex estim in-lin estim non-gaap
dilut ep grow result
increas price target appli
price-to-earnings multipl increas non-gaap dilut ep discount
discount consist profit compani univers
pipelin partnership increasingli import crispr data year
crispr report addit potenti cur data sever beta
thalassemia sickl cell diseas pthi year partner expand allianc last
june includ gene edit therapi dmd also expect clinic start
cellular therapi treat type diabet acquir semma earli phase
ii poc data antitrypsin defici aatd expect year
along phase ii poc start kidney diseas despit
billion extern invest vertex end year cash billion
cf drug may fail clinic gain approv may meet expect
vertex biopharmaceut compani develop innov drug
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
good sold
thousand except per share data
compani report piper sandler co analysi
page
